Explore

Phillips 66 posts surprise profit on higher refining margins

Phillips 66 posts surprise profit on higher refining margins

April 29 (Reuters) - Phillips 66 posted a surprise first-quarter profit on Wednesday, as higher refining margins helped it offset steep losses tied to volatile commodity prices. U.S.

Mondelez beats first-quarter estimates on resilient demand, pricing strength

Mondelez beats first-quarter estimates on resilient demand, pricing strength

April 28 (Reuters) - Oreo-maker Mondelez International beat Wall Street estimates for first-quarter revenue and profit on Tuesday, helped by higher net pricing and resilient demand for its chocolates and biscuits. Shares of the Chicago-based company were up 2% after the bell.

Eli Lilly investors are eager for Foundayo insight after early launch data

Eli Lilly investors are eager for Foundayo insight after early launch data

By Chris Prentice and Mariam Sunny April 29 (Reuters) - Eli Lilly investors will be searching for something they won't find in any first-quarter financial figures reported on Thursday: insight into the launch of weight-loss pill Foundayo.

Taco Bell-parent Yum tops quarterly estimates as value deals fuel demand

Taco Bell-parent Yum tops quarterly estimates as value deals fuel demand

April 29 (Reuters) - Yum Brands beat Wall Street estimates for first-quarter same-store sales growth and profit on Wednesday, as affordable meal offers drove demand at Taco Bell and KFC chains amid economic uncertainty.

General Dynamics beats quarterly estimates on marine, aerospace strength

General Dynamics beats quarterly estimates on marine, aerospace strength

April 29 (Reuters) - General Dynamics on Wednesday beat Wall Street estimates for first-quarter profit and revenue driven by continued strength in its marine and aerospace segments, sending the company's shares up nearly 5% before the bell.

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition away from its once-blockbuster drug, Humira.

Adidas reports strong first-quarter sales and profit despite 'very volatile' market

Adidas reports strong first-quarter sales and profit despite 'very volatile' market

By Linda Pasquini and Helen Reid April 29 (Reuters) - Germany's Adidas on Wednesday reported better-than-expected operating profit in the first quarter, helped by strong demand despite what CEO Bjorn Gulden described as a "very volatile and heavily discounted" retail environment, especially in

PPG beats quarterly profit, revenue estimates on pricing strength

PPG beats quarterly profit, revenue estimates on pricing strength

April 28 (Reuters) - PPG Industries beat Wall Street estimates for first-quarter profit and revenue on Tuesday, helped by price hikes and strong demand in the aerospace and coatings segments.

Smithfield Foods beats quarterly estimates on steady packaged meats demand

Smithfield Foods beats quarterly estimates on steady packaged meats demand

April 28 (Reuters) - Smithfield Foods beat Wall Street estimates for first-quarter sales and profit on Tuesday and stuck to its annual forecasts, helped by steady demand for packaged meat products such as bacon, ham, sausages and hot dogs.

Visa quarterly profit rises on resilient consumer spending

Visa quarterly profit rises on resilient consumer spending

By Pritam Biswas and Rishab Shaju April 28 (Reuters) - Visa reported a higher second-quarter profit on Tuesday as the world's largest payment processor benefited from a steady rise in payment volumes despite ongoing macroeconomic uncertainty, sending its shares up about 4% in extended trading.

Sun Pharma to Acquire Organon in $11.75 Billion Deal to Expand Global Reach

Sun Pharma to Acquire Organon in $11.75 Billion Deal to Expand Global Reach

Sun Pharma to Acquire Organon in $11.75 Billion Deal to Expand Global Reach

Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal

Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal

By Kashish Tandon and Rishika Sadam April 26 (Reuters) - Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co in an all-cash deal valued at about $11.75 billion including debt, for the largest overseas acquisition by an Indian pharmaceutical company.